Beauty Health Co

SKIN remains in a prolonged downtrend under declining moving averages, but extreme oversold conditions and mean-reversion eligibility support a tactical medium-term bounce. Price is still rejecting at key EMAs, so speculative engagement is deferred—looking for evidence of consolidation resolution near the lower support zone before initiating.

• ↑FDA approval for SkinStylus widens microneedling portfolio
• ↑Gross margin rose to 72.2% YoY, reflecting inventory gains
• ↓Revenue fell 6.7% YoY to $64.9M amid tight credit for equipment sales